Inverness Counsel Has Boosted By $5.88 Million Its Amazon.Com (AMZN) Position; Farallon Capital Management Has Lifted By $3.00 Million Its Chemocentryx (CCXI) Stake

Amazon.com, Inc. (NASDAQ:AMZN) Logo

Inverness Counsel Llc increased Amazon.Com Inc (AMZN) stake by 13.63% reported in 2018Q4 SEC filing. Inverness Counsel Llc acquired 3,916 shares as Amazon.Com Inc (AMZN)’s stock rose 1.10%. The Inverness Counsel Llc holds 32,649 shares with $49.04M value, up from 28,733 last quarter. Amazon.Com Inc now has $857.01 billion valuation. The stock increased 1.89% or $32.36 during the last trading session, reaching $1744.72. About 3.46 million shares traded. Amazon.com, Inc. (NASDAQ:AMZN) has risen 13.57% since March 18, 2018 and is uptrending. It has outperformed by 9.20% the S&P500. Some Historical AMZN News: 07/05/2018 – Snap snags new finance chief from Amazon; 30/04/2018 – Augmented Reality Developer Streem Names Liz Pearce as CRO, Bringing Startup, Amazon and Google Experience; 06/03/2018 – Amazon Alexa to Keynote at Connected Car Detroit; 22/03/2018 – MEDIA-Amazon looking for larger Whole Foods stores to support delivery plans- Bloomberg; 15/03/2018 – Jessica Toonkel: Exclusive: Amazon’s internal numbers on Prime Video, revealed GREAT SCOOP by @jldastin; 28/03/2018 – Amazon sheds $52 bln in market value after report on Trump threat; 19/03/2018 – AMAZON SAID TO HAVE LOOKED AT POSSIBILITY OF EXPANDING RETAIL FOOTPRINT BY ACQUIRING SOME LOCATIONS FROM TOYS “R” US – BLOOMBERG, CITING; 19/03/2018 – Alibaba counters Amazon’s expansion in SE Asia; 10/05/2018 – Amazon is building a ‘health & wellness’ team within Alexa as it aims to upend health care; 03/04/2018 – Mike Colter, Gabourey Sidibe, Danny Glover and an All-Star Cast Perform The Radical King for Audible

Farallon Capital Management Llc increased Chemocentryx Inc (CCXI) stake by 26.09% reported in 2018Q4 SEC filing. Farallon Capital Management Llc acquired 300,000 shares as Chemocentryx Inc (CCXI)’s stock rose 6.99%. The Farallon Capital Management Llc holds 1.45 million shares with $15.82 million value, up from 1.15 million last quarter. Chemocentryx Inc now has $546.72 million valuation. The stock increased 2.06% or $0.21 during the last trading session, reaching $10.4. About 658,623 shares traded or 105.05% up from the average. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 12.22% since March 18, 2018 and is uptrending. It has outperformed by 7.85% the S&P500. Some Historical CCXI News: 11/04/2018 – ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting; 09/05/2018 – CHEMOCENTRYX INC – QTRLY DILUTED NET LOSS PER COMMON SHARE $0.19; 23/05/2018 – ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress; 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En; 09/03/2018 – ChemoCentryx 4Q Net $39.7M; 20/04/2018 – DJ Chemocentryx Inc, Inst Holders, 1Q 2018 (CCXI); 09/03/2018 – ChemoCentryx 4Q Rev $56.3M; 13/03/2018 – CHEMOCENTRYX INC CCXI.O : JP MORGAN RAISES TARGET PRICE TO $16 FROM $13; 09/03/2018 ChemoCentryx 4Q EPS 80c; 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA

More notable recent Amazon.com, Inc. (NASDAQ:AMZN) news were published by: Investorplace.com which released: “Is There Something Wrong With Amazon Stock? – Investorplace.com” on March 18, 2019, also Nasdaq.com with their article: “Amazon (AMZN) Dips More Than Broader Markets: What You Should Know – Nasdaq” published on March 14, 2019, Nasdaq.com published: “Buy Amazon (AMZN) Stock on Earnings Growth & E-commerce Dominance? – Nasdaq” on March 13, 2019. More interesting news about Amazon.com, Inc. (NASDAQ:AMZN) were released by: Nasdaq.com and their article: “Amazon’s (AMZN) E-commerce Lead Threatened By New Entrants – Nasdaq” published on March 13, 2019 as well as Nasdaq.com‘s news article titled: “3 Growth Stocks to Buy and Hold for the Next 25 Years – Nasdaq” with publication date: March 16, 2019.

Among 12 analysts covering Amazon.com (NASDAQ:AMZN), 12 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Amazon.com had 18 analyst reports since September 25, 2018 according to SRatingsIntel. The stock has “Buy” rating by Jefferies on Tuesday, September 25. The firm earned “Buy” rating on Monday, March 11 by UBS. Morgan Stanley maintained Amazon.com, Inc. (NASDAQ:AMZN) rating on Thursday, February 28. Morgan Stanley has “Buy” rating and $2200 target. Raymond James maintained Amazon.com, Inc. (NASDAQ:AMZN) rating on Friday, February 1. Raymond James has “Outperform” rating and $1960 target. The firm has “Overweight” rating by Barclays Capital given on Friday, October 26. The company was maintained on Thursday, September 27 by Stifel Nicolaus. KeyBanc Capital Markets upgraded the shares of AMZN in report on Friday, March 15 to “Overweight” rating. The rating was maintained by Bank of America on Wednesday, November 28 with “Buy”. Evercore maintained the stock with “Buy” rating in Monday, March 4 report. On Tuesday, October 23 the stock rating was maintained by Jefferies with “Buy”.

Investors sentiment increased to 1.55 in 2018 Q4. Its up 0.37, from 1.18 in 2018Q3. It is positive, as 93 investors sold AMZN shares while 536 reduced holdings. 184 funds opened positions while 793 raised stakes. 371.97 million shares or 42.70% more from 260.67 million shares in 2018Q3 were reported. Lord Abbett & Ltd reported 128,382 shares. Tiaa Cref Management Limited Liability Company has invested 2.96% in Amazon.com, Inc. (NASDAQ:AMZN). Evanson Asset Management Limited Liability Corp holds 4,429 shares or 1.52% of its portfolio. Moreover, Chevy Chase Tru Inc has 2.87% invested in Amazon.com, Inc. (NASDAQ:AMZN) for 391,297 shares. Hhr Asset Management Limited Liability owns 3.72% invested in Amazon.com, Inc. (NASDAQ:AMZN) for 32,715 shares. Oakworth Cap Inc invested in 1,704 shares. Robeco Institutional Asset Bv stated it has 163,229 shares or 1.1% of all its holdings. Stack Fin Mngmt has 883 shares. Two Sigma Securities Limited Liability has invested 0.01% of its portfolio in Amazon.com, Inc. (NASDAQ:AMZN). Parallax Volatility Advisers Lp reported 23,620 shares stake. Edge Wealth Management Ltd stated it has 2,328 shares. Country Bancorp reported 2.45% in Amazon.com, Inc. (NASDAQ:AMZN). Massachusetts-based S&Co has invested 0.11% in Amazon.com, Inc. (NASDAQ:AMZN). South State stated it has 8,196 shares or 1.42% of all its holdings. Driehaus Mgmt Limited Company owns 181 shares for 0.01% of their portfolio.

Inverness Counsel Llc decreased Cerner Corp (NASDAQ:CERN) stake by 7,330 shares to 18,290 valued at $959,000 in 2018Q4. It also reduced Procter & Gamble (NYSE:PG) stake by 6,480 shares and now owns 156,877 shares. Spon Adr was reduced too.

Since October 29, 2018, it had 0 insider buys, and 10 insider sales for $50.29 million activity. Blackburn Jeffrey M also sold $3.22 million worth of Amazon.com, Inc. (NASDAQ:AMZN) shares. WILKE JEFFREY A sold 1,230 shares worth $1.85M. Shares for $2.70 million were sold by Jassy Andrew R. STONESIFER PATRICIA Q sold $2.31 million worth of stock or 1,375 shares. Shares for $687,447 were sold by Reynolds Shelley on Thursday, November 15. The insider Olsavsky Brian T sold $3.21M. BEZOS JEFFREY P sold $27.69 million worth of stock.

Investors sentiment decreased to 0.93 in 2018 Q4. Its down 0.05, from 0.98 in 2018Q3. It worsened, as 7 investors sold CCXI shares while 38 reduced holdings. 18 funds opened positions while 24 raised stakes. 27.13 million shares or 1.23% more from 26.80 million shares in 2018Q3 were reported. Barclays Public Limited Liability Co holds 5,866 shares. Alliancebernstein Ltd Partnership has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). 14,396 were reported by Zebra Cap Mgmt Limited Liability. 3,800 were reported by Macquarie Group. Clarivest Asset Mgmt Ltd Liability holds 0.01% or 48,300 shares. 22,897 were accumulated by Smith Asset Mgmt Gru L P. Grp One Trading Lp holds 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI) for 13,165 shares. Meeder Asset Mngmt reported 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Ny State Common Retirement Fund holds 25,400 shares. Trexquant Investment LP reported 33,717 shares stake. Citigroup Inc reported 4,073 shares. Franklin Resources reported 1.38M shares or 0.01% of all its holdings. Century has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). D E Shaw Communication Inc has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). 55,800 were accumulated by Strs Ohio.

Since October 16, 2018, it had 0 insider buys, and 8 insider sales for $87.64 million activity. Cappel Markus J. sold 30,237 shares worth $332,779. Schall Thomas J. had sold 7,211 shares worth $86,554. KANAYA SUSAN M sold $457,747 worth of stock. GLAXOSMITHKLINE PLC also sold $85.85 million worth of ChemoCentryx, Inc. (NASDAQ:CCXI) on Tuesday, October 16.

More recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Nasdaq.com which released: “ChemoCentryx (CCXI) Reports Q4 Loss, Lags Revenue Estimates – Nasdaq” on March 11, 2019. Also Nasdaq.com published the news titled: “After-Hours Earnings Report for March 11, 2019 : ADT, COUP, SFIX, DRNA, AVD, PETQ, CCXI, LXFR, MG, OXFD, FRTA, KALA – Nasdaq” on March 11, 2019. Globenewswire.com‘s news article titled: “New Research: Key Drivers of Growth for Ellie Mae, Spotify Technology SA, Bristow Group, Teradata, ChemoCentryx, and AgroFresh Solutions — Factors of Influence, Major Initiatives and Sustained Production – GlobeNewswire” with publication date: February 26, 2019 was also an interesting one.

Farallon Capital Management Llc decreased Bellicum Pharmaceuticals Inc stake by 1.14M shares to 1.00 million valued at $2.92 million in 2018Q4. It also reduced Crinetics Pharmaceuticals In stake by 46,450 shares and now owns 95,365 shares. Spdr S&P 500 Etf Tr (Put) (SPY) was reduced too.

Among 4 analysts covering ChemoCentryx (NASDAQ:CCXI), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ChemoCentryx had 4 analyst reports since November 12, 2018 according to SRatingsIntel. As per Thursday, February 14, the company rating was initiated by Leerink Swann. The rating was maintained by H.C. Wainwright with “Buy” on Tuesday, March 12. On Monday, November 12 the stock rating was maintained by Canaccord Genuity with “Buy”.

ChemoCentryx, Inc. (NASDAQ:CCXI) Institutional Positions Chart

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *